PerkinElmer enters $500M delayed draw term loan to partly fund BioLegend acquisition

REVVITY, INC.

Unsecured term loan facility for $500M to fund portion of BioLegend acquisition, refinance BioLegend debt, and pay fees.
Loan available until earlier of consummation of BioLegend acquisition or five business days after Oct 25, 2021 (possible extension to Jan 31, 2022).
Matures on third anniversary of funding date; interest at base rate or eurocurrency rate plus spread based on debt rating.
Concurrent $500M reduction in existing 364-day senior unsecured bridge term loan facility from Goldman Sachs.
Covenants include debt-to-capitalization ratio (replaced by leverage/interest coverage if below investment grade) and customary events of default.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.